Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Sodium intake and multiple sclerosis activity and progression in BENEFIT
for the BENEFIT Study Group
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
41
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Sodium intake and multiple sclerosis activity and progression in BENEFIT'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
24-h Urinary Sodium Excretion
40%
5-year Follow-up
40%
Active Lesions
20%
Categorical Data Analysis
20%
Clinically Definite multiple Sclerosis
20%
Clinically Isolated Syndrome
40%
Confidence Interval
100%
Cumulative Average
20%
Disability
20%
Disease Activity
20%
Disease Course
20%
Expanded Disability Status Scale
40%
Fast Conversions
20%
Hazard Ratio
60%
High-salt Diet
20%
Imaging Follow-up
20%
Imaging Results
40%
Interferon beta-1a
20%
Magnetic Resonance
20%
Magnetic Resonance Imaging
40%
Multiple Assessments
20%
Multiple Sclerosis
100%
Multiple Sclerosis Treatment
20%
Non-associated
20%
Randomized Clinical Trial
20%
Relapse Rate
20%
Relative Change
20%
Result-oriented
20%
Salt Intake
20%
Sodium Intake
100%
Sodium Levels
40%
Spot Urine
20%
T2 Lesion Volume
20%
Tanaka Formula
20%
Urinary Sodium Concentration
20%
Urinary Sodium Excretion
40%
Nursing and Health Professions
Confidence Interval
83%
Demyelinating Disease
33%
Disease Activity
16%
Disease Course
16%
Expanded Disability Status Scale
33%
Hazard Ratio
50%
Interferon Beta Serine
16%
Lesion Volume
16%
Multiple Sclerosis
100%
Nuclear Magnetic Resonance Imaging
50%
Recurrence Risk
16%
Salt Intake
16%
Sodium Chloride
16%
Sodium Intake
100%
Sodium Urine Level
66%
Urine Sampling
16%
Valerian
16%
Medicine and Dentistry
Clinically Isolated Syndrome
33%
Disease Activity
16%
Disease Course
16%
Expanded Disability Status Scale
33%
Hazard Ratio
50%
High Salt Diet
16%
Interferon Beta Serine
16%
Magnetic Resonance Imaging
50%
Multiple Sclerosis
100%
Randomized Clinical Trial
16%
Recurrence Risk
16%
Salt Intake
16%
Sodium Excretion
33%
Sodium Intake
100%
Urinary System
16%
Urine Sampling
16%
Valerian
16%
Pharmacology, Toxicology and Pharmaceutical Science
Demyelinating Disease
33%
Disease Activity
16%
Disease Course
16%
Expanded Disability Status Scale
33%
Interferon Beta Serine
16%
Multiple Sclerosis
100%
Randomized Clinical Trial
16%
Recurrence Risk
16%
Sodium Chloride
33%
Valerian
16%